dm+d

Unassigned

New Medicines

Allergic conjunctivitis

Information

New molecular entity
Aldeyra Therapeutics
Aldeyra Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

a novel small molecule reactive aldehyde species (RASP) inhibitor that covalently binds free aldehydes and diminishes excessive RASP levels to reduce ocular inflammation [4]
Allergic conjunctivitis is a common allergic disease that affects 20% or more of the population worldwide. The disease is characterized by inflammation of the conjunctiva leading to itching redness and tear production [1].
Allergic conjunctivitis
Topical

Moderate to severe dry eye disease

Information

New molecular entity
Aldeyra Therapeutics
Aldeyra Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

By inhibiting RASP (reactive aldehyde species), which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease
Dry eye syndrome is common, affecting 15-33% of those aged over 65 years. Prevalence increases with age. It is 50% more common in women than in men.
Moderate to severe dry eye disease
Topical